CD248 and its cytoplasmic domain: a therapeutic target for arthritis.

OBJECTIVE CD248 is a transmembrane glycoprotein expressed on the surface of activated perivascular and fibroblast-like cells. This study was undertaken to explore the function of CD248 and its cytoplasmic domain in arthritis. METHODS Synovial tissue biopsy samples from healthy controls, from patients with psoriatic arthritis (PsA), and from patients with rheumatoid arthritis (RA) were stained for CD248. Transgenic mice that were CD248-deficient (CD248-knockout [CD248(KO/KO) ]) or mice with CD248 lacking the cytoplasmic domain (CD248(CyD/CyD) ) were generated. Collagen antibody-induced arthritis (CAIA) was induced in these mice and in corresponding wild-type (WT) mice as controls. Clinical signs and histologic features of arthritis were evaluated. Cytokine levels were determined by enzyme-linked immunosorbent assay, and the number of infiltrating inflammatory cells was quantified by immunohistochemistry. In vitro studies were performed with fibroblasts from CD248-transgenic mouse embryos to explain the observed effects on inflammation. RESULTS Immunostaining of synovium from patients with PsA and patients with RA and that from mice after the induction of CAIA revealed strong CD248 expression in perivascular and fibroblast-like stromal cells. CD248(KO/KO) and CD248(CyD/CyD) mice had less severe arthritis, with lower plasma levels of proinflammatory cytokines, as compared with WT controls. Moreover, the joints of these mice had less synovial hyperplasia, reduced accumulation of inflammatory cells, and less articular cartilage and bone damage. Tumor necrosis factor α-induced monocyte adhesion to CD248(CyD/CyD) fibroblasts was impaired. CD248(CyD/CyD) fibroblasts exhibited reduced expression of hypoxia-inducible factor 1α, placental growth factor, vascular endothelial growth factor, and matrix metalloproteinase 9 activity in response to transforming growth factor β. CONCLUSION CD248 contributes to synovial hyperplasia and leukocyte accumulation in inflammatory arthritis, the effects of which are mediated partly via its cytoplasmic domain. CD248 is therefore a potential new target in the treatment of arthritis.

[1]  T. Thornhill,et al.  Synovial fibroblasts self-direct multicellular lining architecture and synthetic function in three-dimensional organ culture. , 2010, Arthritis and rheumatism.

[2]  Mahlon D. Johnson,et al.  Characterization of TEM1/endosialin in human and murine brain tumors , 2009, BMC Cancer.

[3]  R. Gay,et al.  Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. , 2009, Molecular immunology.

[4]  Yu-Chih Liang,et al.  TGF-β inhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells , 2009, Journal of Biomedical Science.

[5]  R. Gobble,et al.  Differential regulation of human PlGF gene expression in trophoblast and nontrophoblast cells by oxygen tension. , 2009, Placenta.

[6]  S. Kelly,et al.  Basic Synovial Biology and Immunopathology in Psoriatic Arthritis , 2009, The Journal of Rheumatology.

[7]  I. Buysschaert,et al.  Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis , 2009, Arthritis research & therapy.

[8]  Wan-Uk Kim,et al.  Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention , 2009, Mediators of inflammation.

[9]  Hyun-Sook Kim,et al.  Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. , 2009, Arthritis and rheumatism.

[10]  B. Teicher,et al.  Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma , 2008, Clinical Cancer Research.

[11]  G. Haines,et al.  Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. , 2008, Arthritis and rheumatism.

[12]  Erika H. Noss,et al.  The role and therapeutic implications of fibroblast‐like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis , 2008, Immunological reviews.

[13]  M. Salmon,et al.  Fibroblasts as novel therapeutic targets in chronic inflammation , 2008, British journal of pharmacology.

[14]  S. Bohlson,et al.  CD93 and related family members: their role in innate immunity. , 2008, Current drug targets.

[15]  I. Huijbers,et al.  Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma , 2008, Modern Pathology.

[16]  B. Foley,et al.  Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration , 2007, Proceedings of the National Academy of Sciences.

[17]  C. Isacke,et al.  CD248/Endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair , 2007, FEBS letters.

[18]  Mi-Sook Lee,et al.  Interaction of Vascular Endothelial Growth Factor 165 with Neuropilin-1 Protects Rheumatoid Synoviocytes from Apoptotic Death by Regulating Bcl-2 Expression and Bax Translocation1 , 2006, The Journal of Immunology.

[19]  F. Luyten,et al.  Contemporary concepts of inflammation, damage and repair in rheumatic diseases. , 2006, Best practice & research. Clinical rheumatology.

[20]  P. Kovanen,et al.  Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. , 2006, Biochemical and biophysical research communications.

[21]  M. Daha,et al.  The lectin‐like domain of thrombomodulin interferes with complement activation and protects against arthritis , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[23]  J. Lord,et al.  Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. , 2006, Arthritis and rheumatism.

[24]  Amos Bairoch,et al.  ScanProsite: detection of PROSITE signature matches and ProRule-associated functional and structural residues in proteins , 2006, Nucleic Acids Res..

[25]  K. Kinzler,et al.  Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Ritchlin.  Pathogenesis of psoriatic arthritis , 2005, Current opinion in rheumatology.

[27]  A. Roberts,et al.  Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β , 2005, Journal of Cell Science.

[28]  C. Isacke,et al.  Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium , 2005, FEBS letters.

[29]  M. Salmon,et al.  A stromal address code defined by fibroblasts. , 2005, Trends in immunology.

[30]  S. Bohlson,et al.  CD93 interacts with the PDZ domain‐containing adaptor protein GIPC: implications in the modulation of phagocytosis , 2005, Journal of leukocyte biology.

[31]  P. Gasque,et al.  Human Endosialin (Tumor Endothelial Marker 1) Is Abundantly Expressed in Highly Malignant and Invasive Brain Tumors , 2004, Journal of neuropathology and experimental neurology.

[32]  N. Perelman,et al.  Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. , 2003, Blood.

[33]  Seth G. N. Grant,et al.  PDZ Domain Proteins: Plug and Play! , 2003, Science's STKE.

[34]  N. Jenkins,et al.  Molecular Characterization of the MouseTem1/endosialin Gene Regulated by Cell Density in Vitro and Expressed in Normal Tissues in Vivo * , 2001, The Journal of Biological Chemistry.

[35]  F. Eisenhaber,et al.  Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium* , 2001, The Journal of Biological Chemistry.

[36]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[37]  V. Luria,et al.  Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase , 1998, Transgenic Research.

[38]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[39]  J. Thompson,et al.  Increased expression of C1q receptors on neutrophils from inflammatory joint fluids. , 1993, Immunology letters.

[40]  E. Conway,et al.  Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. , 1993, Blood.

[41]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[43]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[44]  S. Ryu,et al.  Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. , 2010, Arthritis and rheumatism.

[45]  D. Schadendorf,et al.  Tumorigenesis and Neoplastic Progression Endosialin ( Tem 1 ) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells , 2010 .

[46]  C. Kallenberg,et al.  Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications. , 2010, Current medicinal chemistry.

[47]  R. Mansel,et al.  Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer , 2004, Clinical & Experimental Metastasis.

[48]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.